Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
CONCLUSIONS: While 5-day ActD and pulsed ActD achieve comparable remission rates, due to its reduced toxicity, ease of administration, and patient convenience, pulsed ActD should be the treatment of choice for MTX-resistant postmolar low-risk GTN.
PMID: 32037196 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Maestá I, Nitecki R, Desmarais CCF, Horowitz NS, Goldstein DP, Elias KM, Berkowitz RS Tags: Gynecol Oncol Source Type: research
More News: Alopecia | Cancer & Oncology | Chemotherapy | Gestational Trophoblastic Tumor | Methotrexate | Study | Thrombocytopenia | Toxicology